Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes

EJ Gianatti; R Hoermann; Q Lam; P Dupuis; JD Zajac; M Grossmann

Journal article

Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes

EJ Gianatti, R Hoermann, Q Lam, P Dupuis, JD Zajac, M Grossmann

Clinical Endocrinology | WILEY | Published : 2016

DOI: 10.1111/cen.12842

Abstract

Objective To assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D). Design Randomized double-blind, parallel, placebo-controlled trial. Patients Men aged 35-70 years with T2D and a total testosterone level ≤12·0 nmol/l (346 ng/dl) at high risk of cardiovascular events, median 10-year United Kingdom Prospective Diabetes Study (UKPDS) coronary heart disease (CHD) risk 21% (IQR 16%, 27%). Eighty-eight participants were randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43). Main Outcome Measures N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTn..

View full abstract

University of Melbourne Researchers

Jeffrey Zajac Author

Mathis Grossmann Author

Related Projects (2)

TESTOSTERONE THERAPY IN MEN WITH TYPE 2 DIABETES MELLITUS

This trial will assess the effect of testosterone injections in men with type 2 diabetes and low testosterone levels on control of their dia..

CONTROL OF MUSCULOSKELETAL FUNCTION AND INSULIN RESISTANCE BY ANDROGENS IN MALES

Male sex hormone or androgen deficiency (AD) is a common, but under-diagnosed condition. AD decreases general well being and contributes to ..

Grants

Awarded by NHMRC

Awarded by CVL Research Grant Pfizer Australia

Funding Acknowledgements

EG was supported by NHMRC Postgraduate Fellowship (#1018196), CVL Research Grant Pfizer Australia (#CR05.09), RACP/Osteoporosis Australia Research Entry Grant and University of Melbourne Postgraduate Scholarship. PD was supported by Bourse du CMDP (Comite des Medecins, Dentistes et Pharmaciens) du CHUQ (Centre Hospitalier Universitaire de Quebec) et de la Fondation du CHUQ - CMDP 2011-2012. MG was supported by an NHMRC Career Development Fellowship (#1024139).